Literature DB >> 31926209

PAK2 activated by Cdc42 and caspase 3 mediates different cellular responses to oxidative stress-induced apoptosis.

John Huang1, Allen Huang2, Amelia Poplawski3, Frank DiPino4, Jolinda A Traugh1, Jun Ling5.   

Abstract

p21-activated protein kinase (PAK2) is a unique member of the PAK family kinases that plays important roles in stress signaling. It can be activated by binding to the small GTPase, Cdc42 and Rac1, or by caspase 3 cleavage. Cdc42-activated PAK2 mediates cytostasis, whereas caspase 3-cleaved PAK2 contributes to apoptosis. However, the relationship between these two states of PAK2 activation remains elusive. In this study, through protein biochemical analyses and various cell-based assays, we demonstrated that full-length PAK2 activated by Cdc42 was resistant to the cleavage by caspase 3 in vitro and within cells. When mammalian cells were treated by oxidative stress using hydrogen peroxide, PAK2 was highly activated through caspase 3 cleavage that led to apoptosis. However, when PAK2 was pre-activated by Cdc42 or by mild stress such as serum deprivation, it was no longer able to be cleaved by caspase 3 upon hydrogen peroxide treatment, and the subsequent apoptosis was also largely inhibited. Furthermore, cells expressing active mutants of full-length PAK2 became more resistant to hydrogen peroxide-induced apoptosis than inactive mutants. Taken together, this study identified two states of PAK2 activation, wherein Cdc42- and autophosphorylation-dependent activation inhibited the constitutive activation of PAK2 by caspase cleavage. The regulation between these two states of PAK2 activation provides a new molecular mechanism to support PAK2 as a molecular switch for controlling cytostasis and apoptosis in response to different types and levels of stress with broad physiological and pathological relevance.
Copyright © 2020 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Apoptosis; Caspase 3; Cdc42; Cytostasis; Oxidative stress; p21-activated kinase 2 (PAK2)

Mesh:

Substances:

Year:  2020        PMID: 31926209     DOI: 10.1016/j.bbamcr.2020.118645

Source DB:  PubMed          Journal:  Biochim Biophys Acta Mol Cell Res        ISSN: 0167-4889            Impact factor:   4.739


  8 in total

Review 1.  Group I PAKs in myelin formation and repair of the central nervous system: what, when, and how.

Authors:  Yan Wang; Fuzheng Guo
Journal:  Biol Rev Camb Philos Soc       Date:  2021-11-22

2.  Lyso-PAF, a biologically inactive phospholipid, contributes to RAF1 activation.

Authors:  Xue Gao; Yijie Liu; Yuancheng Li; Hao Fan; Rong Wu; Rukang Zhang; Brandon Faubert; Yu-Ying He; Marc B Bissonnette; Siyuan Xia; Dong Chen; Hui Mao; Titus J Boggon; Jing Chen
Journal:  Mol Cell       Date:  2022-04-12       Impact factor: 19.328

3.  System-Level Analysis of Alzheimer's Disease Prioritizes Candidate Genes for Neurodegeneration.

Authors:  Jeffrey L Brabec; Montana Kay Lara; Anna L Tyler; J Matthew Mahoney
Journal:  Front Genet       Date:  2021-04-06       Impact factor: 4.599

4.  Pak2 reduction induces a failure of early embryonic development in mice.

Authors:  Juan Zeng; Nengqing Liu; Yinghong Yang; Yi Cheng; Yuanshuai Li; Xiaoxia Guo; Qian Luo; Lifen Zhu; Hongmei Guan; Bing Song; Xiaofang Sun
Journal:  Reprod Biol Endocrinol       Date:  2021-12-09       Impact factor: 5.211

5.  hsa_circ_0013401 Accelerates the Growth and Metastasis and Prevents Apoptosis and Autophagy of Neuroblastoma Cells by Sponging miR-195 to Release PAK2.

Authors:  Shibo Zhu; Xiangliang Tang; Xiaofeng Gao; Jingqi Zhang; Yanhong Cui; Dian Li; Wei Jia
Journal:  Oxid Med Cell Longev       Date:  2021-11-22       Impact factor: 6.543

6.  Effect of Monoacylglycerol Lipase Inhibition on Intestinal Permeability of Rats With Severe Acute Pancreatitis.

Authors:  Jing Wang; Hongwei Xu; Tianjie Chen; Changqin Xu; Xiaohua Zhang; Shule Zhao
Journal:  Front Pharmacol       Date:  2022-04-12       Impact factor: 5.988

7.  CDK4/6 inhibition synergizes with inhibition of P21-Activated Kinases (PAKs) in lung cancer cell lines.

Authors:  Gabriela M Wright; Nick T Gimbrone; Bhaswati Sarcar; Trent R Percy; Edna R Gordián; Fumi Kinose; Natália J Sumi; Uwe Rix; W Douglas Cress
Journal:  PLoS One       Date:  2021-06-17       Impact factor: 3.240

Review 8.  The Use of Nanomedicine to Target Signaling by the PAK Kinases for Disease Treatment.

Authors:  Yiling Wang; Audrey Minden
Journal:  Cells       Date:  2021-12-17       Impact factor: 6.600

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.